evidence table
NAC Respiratory Randomized Trial Evidence Table
Structured evidence table for NAC Respiratory Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| NAC Respiratory Randomized Trial | Results Patients treated with NAC nano-spray demonstrated a significant reduction in WHO mucositis grades and significantly improved OHIP-14 scores compared with the control group (p Conclusions N-acetylcysteine nano-spray appears to be an effective therapeutic option for the management of RIOM, reducing mucositis severity and improving quality of life in oral cancer patients. | 2 | Essam A (2026) | N-acetylcysteine nano-spray versus conventional treatment in the management of radiotherapy-induced oral mucositis in oral cancer patients: a randomized clinical trial. |
| NAC Respiratory Randomized Trial | Background Radiation-induced oral mucositis (RIOM) is a common and debilitating complication of radiotherapy in oral cancer patients, significantly impairing quality of life and potentially interrupting treatment. | 2 | Essam A (2026) | N-acetylcysteine nano-spray versus conventional treatment in the management of radiotherapy-induced oral mucositis in oral cancer patients: a randomized clinical trial. |
| NAC Respiratory Randomized Trial | This study evaluated the therapeutic efficacy of N-acetylcysteine (NAC) nano-spray in managing RIOM, with particular emphasis on mucositis severity, quality of life, and serum gastrin-17 levels. | 2 | Essam A (2026) | N-acetylcysteine nano-spray versus conventional treatment in the management of radiotherapy-induced oral mucositis in oral cancer patients: a randomized clinical trial. |
| NAC Respiratory Randomized Trial | Clinically, it is the standard antidote for acetaminophen (APAP) overdose, restoring hepatic glutathione (GSH) and preventing or mitigating drug-induced liver injury and lowering risk of acute liver failure when administered within the ideal time window.It is also approved as a mucolytic in respiratory disease. | 3 | Qu Hui-Qi (2026) | Redefining the role of the thiol-based agent N -acetylcysteine in human health and disease and elucidating potential advantages of its amide derivative |
| NAC Respiratory Randomized Trial | In this review, these indicators are used only to illustrate the scale and diversification of NAC-related research activity, whereas assessment of therapeutic relevance rests primarily on mechanistic evidence and clinical studies. | 3 | Qu Hui-Qi (2026) | Redefining the role of the thiol-based agent N -acetylcysteine in human health and disease and elucidating potential advantages of its amide derivative |
| NAC Respiratory Randomized Trial | Clinical evidence is evaluated across major disease domains, including pulmonary and hepatic disorders, neuropsychiatric and neurodegenerative conditions, cardiometabolic disease, and oncology, with emphasis on sources of heterogeneity and opportunities for biomarker-guided stratification. | 3 | Qu Hui-Qi (2026) | Redefining the role of the thiol-based agent N -acetylcysteine in human health and disease and elucidating potential advantages of its amide derivative |
| NAC Respiratory Randomized Trial | N 1,2 1 -Acetylcysteine (NAC) straddles two distinct roles: as an established therapeutic agent and as a dietary supplement. | 3 | Qu Hui-Qi (2026) | Redefining the role of the thiol-based agent N -acetylcysteine in human health and disease and elucidating potential advantages of its amide derivative |
Source documents
- N-acetylcysteine nano-spray versus conventional treatment in the management of radiotherapy-induced oral mucositis in oral cancer patients: a randomized clinical trial.
- Redefining the role of the thiol-based agent N -acetylcysteine in human health and disease and elucidating potential advantages of its amide derivative